Table 1

Economic parameters used in the model

ParameterCost (£)95% rangeSource
Cost of screening
 Sample collection15.31(12.5 to 18.63)See online supplementary Appendix A5
 HPV test per sample*9.75(7.23 to 13.03)See online supplementary Appendix A5
 Cytology test per slide*18.15(14.95 to 22.02)See online supplementary Appendix A5
Cost of treatment of neoplasias and cancers
 Colposcopy151.18(124.18 to 184.08)14
 Biopsy79.84(65.35 to 97.71)15
 Excision382.6(313.89 to 468.41)14
 Hysterectomy2583.5(2222.28 to 3039.7714
 Chemotherapy5089(4203.03 to 6188.0016
 Trachalectomy5485.67(4500.32 to 6646.5016
 Radiotherapy19 078(15 709.73 to 23 126.3916
  Stage 14619(4105.25 to 5156.0316 17
  Stage 220 704(17 927.10 to 23 509.7216 17
  Stage 320 387(17 638.43 to 23 509.1816 17
  Stage 417 320(14 953.77 to 20 008.2516 17
QALY loss per screening episode
 Cytology normal, HPV negative0.0001(0.00002 to 0.00023)6–9
 Cytology low-grade, HPV negative, back to routine recall0.0011(0.00023 to 0.002)
 HPV positive, cytology normal, 12 month follow-up cytology0.004(0.00023 to 0.0089)
 Normal outcome at colposcopy0.0147(0.0015 to 0.04)
 CIN1 outcome at colposcopy0.0618(0.005 to 0.11)
 CIN2 outcome at colposcopy0.0783(0.003 to 0.13)
Quality of life weight for different cancer stages18 19
 Stage I0.295(0.19 to 0.51)
 Stage II0.385(0.33 to 0.58)
 Stage III0.44(0.44 to 0.58)
 Stage IV0.52(0.4 to 0.64)
Quality of life weight for different cancer stages post-treatment
 Stage I0.03(0.01 to 0.27)
 Stage II0.065(0.02 to 0.32)
 Stage III0.065(0.02 to 0.32)
 Stage IV0.205(0.031 to 0.53)
  • *Includes consumables, equipment, staff time, and other overheads.

  • CIN, cervical intra-epithelial neoplasia; HPV, human papillomavirus; QOL, quality of life; QUALY, quality-adjusted life-years.